Golden Biotechnology

Taiwan - TaipeiBiotechnology3 H-1B visas (FY2023)

Focus: Golden Biotechnology is a Taiwan-based biotech company focused on developing therapeutic agents for high unmet medical needs, particularly in rare diseases.

Rare Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Golden Biotechnology

AI assessmentNot Hiring

No open roles listed right now. Follow Golden Biotechnology to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

13 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Cell infusion for Dose-finding

Advanced Gastric Cancer

N/A

Clinical Trials (1)

NCT04385641Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer

N/A

Help build intelligence for Golden Biotechnology

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Portfolio depth: Antroquinonol alone spans 6 indications across Phase 1/2 development, offering exposure to oncology, virology, and dermatology
Perfect H1B sponsorship track record with 3 approvals and 0 denials in 2023 demonstrates immigration support
Rare disease and unmet medical need focus aligns with high-impact therapeutic development and potential for breakthrough designations

Watch Out For

No Phase 3 programs yet—meaningful clinical validation and regulatory catalysts are still years away
Zero active job postings and undisclosed employee count signal limited hiring and visibility into organizational scale
Pipeline appears early-stage and unfocused: 13 trials across disparate indications (pancreatic cancer, BPH, COVID-19, atopic dermatitis) raise questions about R&D strategy coherence

Generated by Claude from Golden Biotechnology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

GD Antrodia camphorata

Healthy

N/A

Clinical Trials (1)

NCT01007656A Multiple-Dose Research Study on Safety Evaluation of the GD Antrodia Camphorata in 30 Healthy Adult Subjects

N/A

Umooze

Benign Prostatic Hyperplasia

N/A

Clinical Trials (1)

NCT02313233Research on Benefit of Umooze as Add- on Therapy in Benign Prostatic Hyperplasia

N/A